Literature DB >> 11560289

Modern pharmacotherapies for type 2 diabetes mellitus.

S H Hsia1.   

Abstract

UNLABELLED: CME CreditsThe National Medical Association (NMA) is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education (CME) for physicians.Readers:NMA certifies that when CME material is used as directed it meets the criteria for 2 hours of credit in Category I toward the NMA Physician Achievement Award (PAA) or American Medical Association Physician's Recognition Award (PRA).Each physician should claim only those hours of credit that the physician actually spent in the educational activity. Estimated time for reading the text and taking the CME quiz is approximately 2 hours. The NMA will not maintain any records on individual performance.Physician readers will receive 2 category I credits upon correctly answering a minimum of 70% of the CME questions at the end of this CME article. Physician readers must send the answers to JNMA/CME, 1012 Tenth St., NW, Washington, DC 20001. Answers to the CME questions accompanying this article must be marked by September 25, 2001.Authors:The first or second author of articles published in the Journal of the National Medical Association may claim Category I credit for the NMA PAA or the American Medical Association PRA by including a reprint of the article's first page as part of the PRA or PAA application. APPLICATIONS: PAA application can be obtained by calling NMA's CME office at (202) 347-1895, ext. 241. PRA application can be found by visiting http://www.ama-assn.org/med-sci/pra/prahdr.htm.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11560289      PMCID: PMC2593969     

Source DB:  PubMed          Journal:  J Natl Med Assoc        ISSN: 0027-9684            Impact factor:   1.798


  87 in total

Review 1.  alpha-Glucosidase inhibitors.

Authors:  H E Lebovitz
Journal:  Endocrinol Metab Clin North Am       Date:  1997-09       Impact factor: 4.741

2.  Hepatic dysfunction associated with troglitazone.

Authors:  P B Watkins; R W Whitcomb
Journal:  N Engl J Med       Date:  1998-03-26       Impact factor: 91.245

3.  Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes.

Authors:  R Moses; R Slobodniuk; S Boyages; S Colagiuri; W Kidson; J Carter; T Donnelly; P Moffitt; H Hopkins
Journal:  Diabetes Care       Date:  1999-01       Impact factor: 19.112

4.  A double-blind randomized comparison of meal-related glycemic control by repaglinide and glyburide in well-controlled type 2 diabetic patients.

Authors:  P Damsbo; P Clauson; T C Marbury; K Windfeld
Journal:  Diabetes Care       Date:  1999-05       Impact factor: 19.112

Review 5.  Repaglinide.

Authors:  J A Balfour; D Faulds
Journal:  Drugs Aging       Date:  1998-08       Impact factor: 3.923

6.  Repaglinide/troglitazone combination therapy: improved glycemic control in type 2 diabetes.

Authors:  P Raskin; L Jovanovic; S Berger; S Schwartz; V Woo; R Ratner
Journal:  Diabetes Care       Date:  2000-07       Impact factor: 19.112

Review 7.  Rosiglitazone.

Authors:  J A Balfour; G L Plosker
Journal:  Drugs       Date:  1999-06       Impact factor: 9.546

8.  Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group.

Authors:  S Schwartz; P Raskin; V Fonseca; J F Graveline
Journal:  N Engl J Med       Date:  1998-03-26       Impact factor: 91.245

9.  Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.

Authors:  V Fonseca; J Rosenstock; R Patwardhan; A Salzman
Journal:  JAMA       Date:  2000-04-05       Impact factor: 56.272

10.  Metabolic effects of metformin addition to chronic glibenclamide treatment in type 2 diabetes.

Authors:  S Marena; V Tagliaferro; G Montegrosso; A Pagano; L Scaglione; G Pagano
Journal:  Diabete Metab       Date:  1994 Jan-Feb
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.